Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 28 Novo Nordisk has leading positions in diabetes, obesity and haemophilia Diabetes Market value Obesity Market value Haemophilia Market value Novo Nordisk value market share bDKK Global market position bDKK Novo Nordisk value market share Global market position bDKK Novo Nordisk value market share Global market position #1 600 50% 10 #1 50% #2 80 50% 70 500 40% 8 40% 40% 60 400 30% 6 30% 50 30% 300 40 20% 4 CAGR¹ value: 16.4% CAGR² value: 18.0% - 20% 30 CAGR¹ value: 1.9% 20% 200 20 10% 2 10% 10% 100 10 0% 0% 0% Aug 2013 Aug 2018 1 CAGR for 5-year period Source: IQVIA MAT Aug, 2018 value figures Aug 2016 Note: Global value data Aug 2018 FY 2013 FY 2017 2 CAGR for 2-year period Source: IQVIA MAT Aug, 2018 value figures changing diabetes® 3 CAGR for 5-year period Note: Annual sales figures for Haemophilia A, B and Bypassing agents segment. Recombinant and plasma. derived products Source: Company reports novo nordisk

View entire presentation